Valuation: Agenus Inc.

Market Cap 268M 235M 219M 201M 378M 25.66B 383M 2.6B 1.02B 12.67B 1B 983M 43.8B P/E 2026 *
8.99x
P/E 2027 * -37.4x
Enterprise Value 268M 235M 219M 201M 378M 25.66B 383M 2.6B 1.02B 12.67B 1B 983M 43.8B EV / Sales 2026 *
1.45x
EV / Sales 2027 * 2.04x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day+2.17%
1 week+23.74%
Current month+100.98%
1 month+95.24%
3 months+50.37%
6 months+92.79%
Current year+95.86%
1 week 4.99
Extreme 4.99
6.23
1 month 2.96
Extreme 2.96
8.7
Current year 2.71
Extreme 2.71
8.7
1 year 2.71
Extreme 2.71
8.7
3 years 1.38
Extreme 1.38
32
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Chief Executive Officer

4,852 0.0117%
01/07/26 Free

Director

8,547 0.0205%
01/07/26 Free

Director

2,268 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
+2.17%+23.74%-3.15%-78.79% 268M
+2.08%-0.99%-1.03%+11.57% 46.86B
-0.55%+3.87%+402.87%+644.42% 40.23B
+0.32%+5.29%+11.03%+56.09% 36.23B
+1.71%+3.66%+6.87%-5.88% 34.72B
+0.62%+1.65%+5.41%+43.89% 27.89B
-0.76%+13.09%+31.78%+139.89% 16.79B
+0.07%+0.87% - - 16.74B
+0.78%-5.88%+2.29%+7.76% 13.12B
+1.95%+1.40%-11.15%-30.26% 12.7B
Average +0.80%+2.81%+49.44%+87.63% 24.55B
Weighted average by Cap. +0.69%+1.07%+75.91%+137.95%

Financials

2026 *2027 *
Net sales 185M 162M 151M 139M 261M 17.71B 264M 1.8B 702M 8.75B 693M 678M 30.23B 131M 116M 108M 98.79M 186M 12.61B 188M 1.28B 499M 6.22B 493M 483M 21.51B
Net income 44.8M 39.38M 36.66M 33.67M 63.22M 4.3B 64.06M 436M 170M 2.12B 168M 165M 7.33B -17.8M -15.65M -14.57M -13.38M -25.12M -1.71B -25.45M -173M -67.62M -843M -66.82M -65.38M -2.91B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
27/07/26 US$6.150 +2.84% 900,044
24/07/26 US$5.980 -3.39% 1,249,283
23/07/26 US$6.190 +11.93% 2,333,435
22/07/26 US$5.530 -0.90% 1,698,697
21/07/26 US$5.580 +12.27% 2,602,570
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.980USD
Average target price
30.00USD
Spread / Average Target
+401.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock